Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 7/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.52 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.52 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | LIG1 | P18858 | 1/20 | 0.47 |
| ▸ | LOX | P28300 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23314108 | 0.84 | PKM (0.54) | DAOLMNAPPARGNCOA2NCOA1 | |
| SCHEMBL15836205 | 0.83 | LMNA (0.47) | DAOLMNAPPARGNCOA2NCOA1 | |
| SCHEMBL14284027 | 0.82 | NPSR1 (0.77) | LMNAPPARGNCOA2NCOA1NPSR1 | |
| SCHEMBL3131211 | 0.82 | F2 (0.50) | DAOLMNAPPARGNCOA2NCOA1 | |
| SCHEMBL7893780 | 0.82 | LMNA (0.46) | DAOLMNAPPARGNCOA2NCOA1 | |
| SCHEMBL15851416 | 0.81 | LMNA (0.48) | DAOLMNAPPARGNCOA2NCOA1 | |
| SCHEMBL2522107 | 0.80 | LMNA (0.49) | DAOLMNAPPARGNCOA2NCOA1 | |
| SCHEMBL16237287 | 0.79 | DAO (0.52) | DAOLMNAPPARGNCOA2NCOA1 | |
| SCHEMBL312149 | 0.79 | CA2 (0.47) | DAOLMNAPPARGNCOA2NCOA1 | |
| SCHEMBL7895808 | 0.79 | LMNA (0.47) | DAOLMNAPPARGNCOA2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 280 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102947310-B | Fused pyridine compounds as dual modulators of the 5-HT2A and D3 receptors | HOFFMAN-LA ROCHE LTD. (CH) | 2015-11-25 | — | — | CN | claimed |
| CN-103501780-B | Benzofuran-piperidine compounds | HOFFMAN-LA ROCHE LTD. (CH) | 2015-11-25 | — | — | CN | claimed |
| CN-102958936-B | The pyridine compounds condensed | HOFFMAN-LA ROCHE LTD. (CH) | 2015-10-21 | — | — | CN | claimed |
| CN-103501780-A | Novel benzofurane-piperidine compounds | HOFFMANN LA ROCHE | 2014-01-08 | — | — | CN | claimed |
| CN-101384581-B | Benzoyl-piperidine derivatives as 5HT2/D3 modulators | HOFFMANN LA ROCHE | 2013-09-18 | — | — | CN | claimed |
| CN-103261190-A | Novel benzofurane compounds | HOFFMANN LA ROCHE | 2013-08-21 | — | — | CN | claimed |
| CN-102958936-A | Anellated pyridine compounds | HOFFMANN LA ROCHE | 2013-03-06 | — | — | CN | claimed |
| CN-102947310-A | Fused pyridine compounds as dual modulators of the 5-HT2A and D3 receptors | HOFFMANN LA ROCHE | 2013-02-27 | — | — | CN | claimed |
| US-20120214817-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | MARYANOFF BRUCE E (US) | 2012-08-23 | — | — | US | claimed |
| CN-101410116-A | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-15 | — | — | CN | claimed |
| EP-1987019-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS 5HT2/D3 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-11-05 | — | — | EP | claimed |
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2008-10-02 | — | — | US | claimed |
| WO-2007093540-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS 5HT2/D3 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | claimed |
| US-20070197531-A1 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | claimed |
| US-20070191391-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | US | claimed |
| US-7160905-B2 | Hydroxyethylene compounds with Asp2 inhibitory activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-01-09 | — | — | US | claimed |
| US-7030112-B2 | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-18 | — | — | US | claimed |
| US-20050038028-A1 | Hydroxyethylene compounds with asp2 inhibitory activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-02-17 | — | — | US | claimed |
| EP-1448516-A1 | HYDROXYETHYLENE COMPOUNDS WITH ASP2 INHIBITORY ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2004-08-25 | — | — | EP | claimed |
| WO-2003045903-A1 | HYDROXYETHYLENE COMPOUNDS WITH ASP2 INHIBITORY ACTIVITY | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-06-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197531-A1 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HTR2A, HTR3A, HTR2C | DAO 2593/4885LMNA 3403/4885PPARG 1703/4885 |
| US-20120214817-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, PLAUR, BDKRB2 | DAO 1503/4885LMNA 2503/4885PPARG 2419/4885 |
| US-20050038028-A1 | Hydroxyethylene compounds with asp2 inhibitory activity | BACE2, BACE1, PSEN2 | DAO 2983/4885LMNA 1392/4885PPARG 3201/4885 |
| US-20070191391-A1 | Urotensin II receptor antagonists | UTS2R, PLAUR, BDKRB2 | DAO 1503/4885LMNA 2503/4885PPARG 2419/4885 |
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | CTSS, CTSB, CTSZ | DAO 1273/4885LMNA 2096/4885PPARG 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.